SCHEDULE 13G Filed 2026-08-14 Event — SEC 0001104659-26-097423 →

ADAR1 Capital Management, LLC → Research Alliance Corporation III RACC

Stake: — Shares: — Class: Class A Ordinary Shares, par value $0.0001 per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

2 transactions

2 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

11 filings by this filer

10 other filings in the data moat

Short Interest · settle 2026-07-31

DTC 1.00

7,344 shares short · -20.8% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-05-21	Research Alliance Holdings III LLC /Cayman	director, 10%+ owner	Award	275,000	$10.00	$2.75M
2026-05-21	Hammond Matthew	director, officer, 10%+ owner	Award	275,000	$10.00	$2.75M

Other 13D/G Filings on Research Alliance Corporation III

Filed	Form	Filer	Stake	Shares
2026-08-03	SCHEDULE 13G	BANK OF AMERICA CORP /DE/	—	—	view →
2026-07-28	SCHEDULE 13D/A	Research Alliance Holdings III LLC /Cayman	—	1,520,269	view →
2026-05-29	SCHEDULE 13D	Research Alliance Holdings III LLC /Cayman	14.70%	1,520,269	view →
2026-05-29	SCHEDULE 13G	BIOTECHNOLOGY VALUE FUND L P	—	—	view →
2026-05-28	SCHEDULE 13G	Commodore Capital LP	—	—	view →

Other Filings by ADAR1 Capital Management, LLC

Filed	Form	Issuer	Stake	Shares
2026-08-14	SCHEDULE 13G	Rein Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Cyclerion Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Pliant Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Editas Medicine, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	JATT II Acquisition Corp.	—	—	view →
2026-08-14	SCHEDULE 13G	Amanat Acquisition Corp.	—	—	view →
2026-08-14	SCHEDULE 13G	Boundless Bio, Inc.	—	—	view →
2026-06-05	SCHEDULE 13G	Rallybio Corporation RLYB	—	—	view →
2026-06-05	SCHEDULE 13G	InMed Pharmaceuticals, Inc. INM	—	—	view →
2025-04-28	SCHEDULE	Keros Therapeutics, Inc. KROS	13.29%	5,390,964	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →